Results 301 to 310 of about 436,801 (327)

The Editor’s Roundtable: High-Density Lipoprotein Cholesterol

The American Journal of Cardiology, 2007
r. Friedewald has no relevant financial relationship to isclose. Dr. Brewer has received fees for consulting from erck, White House Station, New Jersey; Merck/Schering lough, North Wales, Pennsylvania; Lipid Sciences, Pleasnton, California; Pfizer, Inc., New York, New York; Noartis, East Hanover, New Jersey; sanofi-aventis, Bridgewaer, New Jersey.
Vincent E, Friedewald, H Brian, Brewer, Scott M, Grundy, Daniel J, Rader, William C, Roberts   +4 more
openaire   +2 more sources

Seasonal variation in high density lipoprotein cholesterol

Atherosclerosis, 1993
We investigated the seasonal variation in high density lipoprotein cholesterol (HDL) in 142 dyslipidemic (non-HDL-cholesterol > or = 5.2 mmol/l) middle-aged men in the placebo group of the Helsinki Heart Study over the 5-year trial period. A seasonal pattern was found in HDL fluctuation, with a 4.5% drop during mid-winter (5-year mean 1.192 +/- 0.265 ...
M, Mänttäri, K, Javela, P, Koskinen, J, Pikkarainen, V, Manninen, J K, Huttunen, M H, Frick   +6 more
openaire   +2 more sources

Terbutaline Raises High-Density-Lipoprotein-Cholesterol Levels

New England Journal of Medicine, 1981
HIGH-density-lipoprotein (HDL) cholesterol has been found to be the best serum predictor of coronary-artery disease.
P L, Hooper, W, Woo, L, Visconti, D R, Pathak   +3 more
openaire   +2 more sources

High-density lipoprotein cholesterol

Current Opinion in Endocrinology, Diabetes & Obesity, 2015
We provide a historical perspective of how high-density lipoprotein (HDL) cholesterol became a clinical standard, the evidence in favor of HDL function as a more appropriate indication of HDL's antiatherogenic nature, and the options ahead.Recent studies have demonstrated a strong relationship between the cholesterol efflux capacity of plasma and ...
openaire   +2 more sources

High Density Lipoprotein Cholesterol and Statin Trials

Current Medicinal Chemistry, 2008
Epidemiological studies show that high density lipoprotein cholesterol (HDL-C) levels are inversely related to the risk of vascular events. Statins are the most widely prescribed drugs for the treatment of dyslipidaemias and their use for the prevention of vascular events is evidence based. Statins raise HDL-C but this effect seems to vary considerably
Anna, Kakafika, Vasilios G, Athyros, Konstantinos, Tziomalos, Asterios, Karagiannis, Dimitri P, Mikhailidis   +4 more
openaire   +2 more sources

Raising high density lipoprotein cholesterol

Biochemical Pharmacology, 1990
The predictive pawer of plasma density lipaprotein (HDL*) cholesterol concentration for the development of coronary heart disease (CHD) has now been demonstrated in four large studies in the U.S.A. (Framingham Heart Study, Lipid Research Clinics-Coronary Primary Prevention Trial [LRCCPPT], LRC Follow-up Study and Multiple Risk Factor Intervention Trial)
openaire   +1 more source

High-Density Lipoprotein Cholesterol and Liver Disease

Hepatology, 1983
To establish whether there is any significant relationship between high-density lipoprotein cholesterol (HDLC) concentrations and biopsy-documented liver disease, 169 patients had needle biopsies, serum cholesterol, and HDLC evaluated.
G C, Kanel, G, Radvan, R L, Peters
openaire   +2 more sources

High-density lipoprotein cholesterol

Postgraduate Medicine, 1990
Evidence from epidemiologic, lipid intervention, and coronary angiographic studies demonstrates the importance of high-density lipoprotein cholesterol (HDL-C) in coronary artery disease (CAD) risk. Data from these studies strongly support the measurement of HDL-C in all patients screened for CAD.
Lavie, CJ, Okeefe, JH, Blonde, L, Gau, GT   +3 more
openaire   +2 more sources

High-Density Lipoprotein Cholesterol Measurements

JAMA, 1986
Often, plasma high-density lipoprotein cholesterol (HDLC) measurements lack sufficient accuracy to be of practical use in an individual clinical setting. Recent clinical investigations have demonstrated the strong predictive value of HDLC concentration for future coronary events and rate of progression of angiographically assessed coronary ...
openaire   +1 more source

Effect of Low-Dose Niacin on High-Density Lipoprotein Cholesterol and Total Cholesterol/High-Density Lipoprotein Cholesterol Ratio

Archives of Internal Medicine, 1988
Niacin significantly alters blood lipid concentrations but its use has been limited because of clinically disturbing side effects. In an attempt to circumvent these drawbacks, 55 patients with cardiovascular disease were given low-dose long-acting niacin, 1 g/d.
openaire   +2 more sources